Vulvar and Vaginal Atrophy (VVA) Therapy Market Segmentation:
Treatment Segment Analysis
The global vulvar and vaginal atrophy (VVA) therapy market is segmented and analyzed for demand and supply by treatment into non-hormonal therapy, hormonal therapy, and laser therapy. Out of these types of treatment, the hormonal therapy segment is estimated to gain the largest market share in the year 2035. The growth of the segment can be attributed to the growing number of vaginal cancer cases as the therapy lessens the chances of cancer recurrence. For instance, according to the Centers for Disease Control and Prevention, in 2019, around 1,368 women were diagnosed with vaginal cancer in the United States. On the other hand, most women have menopausal hormone therapy (MHT) also known as hormone replacement therapy (HRT) if they experience symptoms associated with menopause. Additionally, hormonal therapy is also used to treat breast cancer using hormones to grow. Hence, such a higher utilization is anticipated to spike the segment growth over the forecast period.
Diagnosis Segment Analysis
The global vulvar and vaginal atrophy (VVA) therapy market is also segmented and analyzed for demand and supply by diagnosis into pelvic examination, urine test, and acid balance test. Amongst these three segments, the urine test segment is expected to garner a significant share in the year 2035. Urine test is done since they can diagnose almost every type of disorder including UTI, Diabetes, kidney diseases, vaginal cancer, and others. To check for UTI, urine is examined via a microscope to look for bacteria or white blood cells, major signs of infection.
Our in-depth analysis of the global market includes the following segments:
|
By Symptoms |
|
|
By Diagnosis |
|
|
By Treatment |
|
|
By End-User |
|
